Coherus Oncology (FRA:8C5) Tariff Resilience Score: 7/10 (As of Jul. 12, 2026)


FRA:8C5 Coherus Oncology Inc FRA:8C5
44 GF Score
Price €1.40
GF Value €0.64
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology Tariff Resilience Score?

Coherus Oncology FRA:8C5 -2.10% 44 Tariff Resilience Score is 7 as of Jul. 12, 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 44/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,370 Biotechnology companies, Coherus Oncology ranks better than 90.36% on this metric.

Coherus Oncology has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Coherus Oncology has Coherus BioSciences imports active pharmaceutical ingredients but benefits from industry-specific tariff exemptions. The company has diversified its supplier base and has moderate pricing power, reducing tariff vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Coherus Oncology might have Highly Resilient.

Coherus Oncology  (FRA:8C5) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Coherus Oncology Tariff Resilience Score Related Terms

FRA:8C5 vs TARA, KPTI, CNTN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Coherus Oncology's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Tariff Resilience Score falls into.


FRA:8C5
44GF Score
Coherus Oncology Inc FRA:8C5
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Coherus Oncology (FRA:8C5) has a Tariff Resilience Score of 7 as of Jul. 12, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Coherus Oncology ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Coherus Oncology's Tariff Resilience Score too high?
Coherus Oncology's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Coherus Oncology's value of 7 is 75% above this industry median. Based on the distribution chart, Coherus Oncology ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coherus Oncology has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Tariff Resilience Score compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #132 out of 1370 companies for Tariff Resilience Score. This places Coherus Oncology in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Coherus Oncology's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €1.40 — trading 118.6% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Coherus Oncology's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Tariff Resilience Score is 7 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.40 is trading 118.6% above its estimated GF Value™ of €0.64. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

  • Tariff Resilience Score: 7
  • GF Value™: €0.64 vs. price of €1.40 (118.6% above fair value)
  • GF Score™: 44/100 with 6 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1370)

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
44GF Score

Get the complete analysis for FRA:8C5

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40
Price
€0.64
GF Value